UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 肺癌の化学予防 chemoprevention of lung cancer
2. 子宮頚部細胞診：異型扁平上皮細胞（ASC-USおよびASC-H）の評価 cervical cytology evaluation of atypical squamous cells asc us and asc h
3. 頭頸部腫瘍の病理 pathology of head and neck neoplasms
4. 炎症性腸疾患における大腸癌のサーべイランス colorectal cancer surveillance in inflammatory bowel disease
5. モノクローナル蛋白の認識 recognition of monoclonal proteins

English Journal

Premalignant PTEN-deficient thymocytes activate microRNAs miR-146a and miR-146b as a cellular defense against malignant transformation.

Burger ML, Xue L, Sun Y, Kang C, Winoto A.
Blood.Blood.2014 Jun 26;123(26):4089-100. doi: 10.1182/blood-2013-11-539411. Epub 2014 Apr 15.
Cancer develops by a multistep process during which cells acquire characteristics that allow them to evade apoptosis and proliferate unchecked. Sequential acquisition of genetic alterations drives this process but also causes cellular stress, frequently prompting cells to enter a premalignant period
PMID 24735967

Loss of miR-125a expression in a model of K-ras-dependent pulmonary premalignancy.

Liclican EL1, Walser TC2, Hazra S1, Krysan K3, Park SJ1, Pagano PC4, Gardner B5, Larsen JE6, Minna JD7, Dubinett SM8.
Cancer prevention research (Philadelphia, Pa.).Cancer Prev Res (Phila).2014 Jun 9. pii: canprevres.0063.2014. [Epub ahead of print]
Understanding the molecular pathogenesis of lung cancer is necessary to identify biomarkers/targets specific to individual airway molecular profiles and to identify options for targeted chemoprevention. Herein, we identify mechanisms by which loss of microRNA (miRNA)-125a-3p (miR-125a) contributes t
PMID 24913817

GATA2 is epigenetically repressed in human and mouse lung tumors and is not requisite for survival of KRAS mutant lung cancer.

Tessema M1, Yingling CM, Snider AM, Do K, Juri DE, Picchi MA, Zhang X, Liu Y, Leng S, Tellez CS, Belinsky SA.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.J Thorac Oncol.2014 Jun;9(6):784-93. doi: 10.1097/JTO.0000000000000165.
INTRODUCTION: GATA2 was recently described as a critical survival factor and therapeutic target for KRAS mutant non-small-cell lung cancer (NSCLC). However, whether this role is affected by epigenetic repression of GATA2 in lung cancer is unclear.METHODS: GATA2 expression and promoter CpG island met
PMID 24807155

Treatment outcome of Photofrin-based photodynamic therapy for T1 and T2 oral squamous cell carcinoma and dysplasia

Ikeda Hisazumi,Tobita Takayoshi,Ohba Seigo,Uehara Masataka,Asahina Izumi
Photodiagnosis and Photodynamic Therapy 10(3), 229-235, 2013-09
… Background: Photodynamic therapy (PDT) is a minimally invasive treatment modality for early and superficial malignancy or premalignancy in the head and neck regions. …
NAID 120005345404

Assessment of Ki-67 in Healthy, Premalignant, and Malignant Lesions of the Oral Mucosa and its Predictive Role in Disease Progression

Reddy. M Vandana,Saxena Susmita
International Journal of Oral-Medical Sciences 9(2), 67-74, 2010
… labeling index was expressed as the ratio of the number of cells stained by MIB-1 to the total number of cells counted per section (minimum of 1000 cells in consecutive fields).Results : The mean Ki-67 labeling index score was 8.47±1.586 in healthy oral mucosa, 25.5±3.01 in premalignancy, and 29.7±3.04 in squamous cell carcinoma.Conclusion : The antibody MIB-1 represents a robust and easily applicable marker of cell proliferation whose expression correlates well with the disease progression from premalignancy to …
NAID 130000417574